Suven Life Sciences Limited (NSE: SUVEN.NS) Stock Competitors & Peer Comparison

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SUNPHARMA.NS trades at ₹1,804.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SUNPHARMA.NS's P/E ratio is 35.04. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, SUVEN.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check SUNPHARMA.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SUNPHARMA.BO trades at ₹1,801.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SUNPHARMA.BO's P/E ratio is 35.31. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, SUVEN.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check SUNPHARMA.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, DIVISLAB.BO has a market cap of 2.5T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while DIVISLAB.BO trades at ₹9,545.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas DIVISLAB.BO's P/E ratio is 86.62. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to DIVISLAB.BO's ROE of +0.18%. Regarding short-term risk, SUVEN.NS is less volatile compared to DIVISLAB.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check DIVISLAB.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, DIVISLAB.NS has a market cap of 2.5T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while DIVISLAB.NS trades at ₹9,550.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas DIVISLAB.NS's P/E ratio is 86.70. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to DIVISLAB.NS's ROE of +0.18%. Regarding short-term risk, SUVEN.NS is less volatile compared to DIVISLAB.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check DIVISLAB.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, TORNTPHARM.BO has a market cap of 1.8T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while TORNTPHARM.BO trades at ₹4,778.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas TORNTPHARM.BO's P/E ratio is 72.50. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to TORNTPHARM.BO's ROE of +0.20%. Regarding short-term risk, SUVEN.NS is more volatile compared to TORNTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check TORNTPHARM.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, TORNTPHARM.NS has a market cap of 1.8T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while TORNTPHARM.NS trades at ₹4,772.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas TORNTPHARM.NS's P/E ratio is 71.50. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to TORNTPHARM.NS's ROE of +0.20%. Regarding short-term risk, SUVEN.NS is more volatile compared to TORNTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check TORNTPHARM.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ZYDUSLIFE.BO has a market cap of 1.2T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ZYDUSLIFE.BO trades at ₹1,160.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ZYDUSLIFE.BO's P/E ratio is 27.32. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ZYDUSLIFE.BO's ROE of +0.16%. Regarding short-term risk, SUVEN.NS is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ZYDUSLIFE.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ZYDUSLIFE.NS has a market cap of 1.2T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ZYDUSLIFE.NS trades at ₹1,159.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ZYDUSLIFE.NS's P/E ratio is 27.15. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ZYDUSLIFE.NS's ROE of +0.16%. Regarding short-term risk, SUVEN.NS is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ZYDUSLIFE.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, LAURUSLABS.BO has a market cap of 1.1T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while LAURUSLABS.BO trades at ₹2,054.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas LAURUSLABS.BO's P/E ratio is 101.13. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to LAURUSLABS.BO's ROE of +0.21%. Regarding short-term risk, SUVEN.NS is less volatile compared to LAURUSLABS.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check LAURUSLABS.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, LAURUSLABS.NS has a market cap of 1.1T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while LAURUSLABS.NS trades at ₹2,050.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas LAURUSLABS.NS's P/E ratio is 101.18. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to LAURUSLABS.NS's ROE of +0.21%. Regarding short-term risk, SUVEN.NS is less volatile compared to LAURUSLABS.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check LAURUSLABS.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while CIPLA.BO trades at ₹1,343.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas CIPLA.BO's P/E ratio is 32.21. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to CIPLA.BO's ROE of +0.10%. Regarding short-term risk, SUVEN.NS is more volatile compared to CIPLA.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check CIPLA.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while CIPLA.NS trades at ₹1,340.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas CIPLA.NS's P/E ratio is 32.15. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, SUVEN.NS is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check CIPLA.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while MANKIND.NS trades at ₹2,500.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas MANKIND.NS's P/E ratio is 47.83. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, SUVEN.NS is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check MANKIND.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while MANKIND.BO trades at ₹2,485.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas MANKIND.BO's P/E ratio is 47.54. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, SUVEN.NS is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check MANKIND.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, DRREDDY.BO has a market cap of 1T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while DRREDDY.BO trades at ₹1,209.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas DRREDDY.BO's P/E ratio is 30.43. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, SUVEN.NS is more volatile compared to DRREDDY.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check DRREDDY.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, DRREDDY.NS has a market cap of 1T. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while DRREDDY.NS trades at ₹1,208.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas DRREDDY.NS's P/E ratio is 30.42. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, SUVEN.NS is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check DRREDDY.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AUROPHARMA.NS has a market cap of 974B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AUROPHARMA.NS trades at ₹1,692.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AUROPHARMA.NS's P/E ratio is 26.45. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, SUVEN.NS is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check AUROPHARMA.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AUROPHARMA.BO has a market cap of 972B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AUROPHARMA.BO trades at ₹1,690.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AUROPHARMA.BO's P/E ratio is 26.41. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, SUVEN.NS is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check AUROPHARMA.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, LUPIN.BO has a market cap of 927.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while LUPIN.BO trades at ₹2,035.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas LUPIN.BO's P/E ratio is 15.97. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to LUPIN.BO's ROE of +0.26%. Regarding short-term risk, SUVEN.NS is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check LUPIN.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, LUPIN.NS has a market cap of 927.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while LUPIN.NS trades at ₹2,029.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas LUPIN.NS's P/E ratio is 15.93. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to LUPIN.NS's ROE of +0.26%. Regarding short-term risk, SUVEN.NS is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check LUPIN.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GLENMARK.BO has a market cap of 661.2B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GLENMARK.BO trades at ₹2,288.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GLENMARK.BO's P/E ratio is 35.94. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GLENMARK.BO's ROE of +0.19%. Regarding short-term risk, SUVEN.NS is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check GLENMARK.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GLENMARK.NS has a market cap of 652.2B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GLENMARK.NS trades at ₹2,311.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GLENMARK.NS's P/E ratio is 37.88. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GLENMARK.NS's ROE of +0.19%. Regarding short-term risk, SUVEN.NS is more volatile compared to GLENMARK.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check GLENMARK.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ALKEM.NS has a market cap of 632.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ALKEM.NS trades at ₹5,292.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ALKEM.NS's P/E ratio is 29.29. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ALKEM.NS's ROE of +0.16%. Regarding short-term risk, SUVEN.NS is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ALKEM.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ALKEM.BO has a market cap of 629.1B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ALKEM.BO trades at ₹5,262.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ALKEM.BO's P/E ratio is 29.20. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ALKEM.BO's ROE of +0.16%. Regarding short-term risk, SUVEN.NS is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ALKEM.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, IPCALAB.BO has a market cap of 497.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while IPCALAB.BO trades at ₹1,946.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas IPCALAB.BO's P/E ratio is 36.76. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to IPCALAB.BO's ROE of +0.16%. Regarding short-term risk, SUVEN.NS is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check IPCALAB.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GLAND.NS has a market cap of 495.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GLAND.NS trades at ₹3,006.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GLAND.NS's P/E ratio is 43.84. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, SUVEN.NS is less volatile compared to GLAND.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check GLAND.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GLAND.BO has a market cap of 495.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GLAND.BO trades at ₹3,006.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GLAND.BO's P/E ratio is 43.87. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GLAND.BO's ROE of +0.11%. Regarding short-term risk, SUVEN.NS is less volatile compared to GLAND.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check GLAND.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, IPCALAB.NS has a market cap of 493.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while IPCALAB.NS trades at ₹1,945.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas IPCALAB.NS's P/E ratio is 36.54. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to IPCALAB.NS's ROE of +0.16%. Regarding short-term risk, SUVEN.NS is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check IPCALAB.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AJANTPHARM.NS has a market cap of 446.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AJANTPHARM.NS trades at ₹3,573.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AJANTPHARM.NS's P/E ratio is 39.38. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, SUVEN.NS is more volatile compared to AJANTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check AJANTPHARM.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AJANTPHARM.BO has a market cap of 446.2B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AJANTPHARM.BO trades at ₹3,576.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AJANTPHARM.BO's P/E ratio is 39.42. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, SUVEN.NS is more volatile compared to AJANTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check AJANTPHARM.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SUVENPHAR.NS's ROE of +0.03%. Regarding short-term risk, SUVEN.NS is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check SUVENPHAR.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, SUVEN.NS is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check SUVENPHAR.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, EMCURE.NS has a market cap of 364.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while EMCURE.NS trades at ₹1,922.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas EMCURE.NS's P/E ratio is 35.14. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to EMCURE.NS's ROE of +0.21%. Regarding short-term risk, SUVEN.NS is less volatile compared to EMCURE.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check EMCURE.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, NEULANDLAB.NS has a market cap of 281.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while NEULANDLAB.NS trades at ₹21,905.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas NEULANDLAB.NS's P/E ratio is 55.71. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to NEULANDLAB.NS's ROE of +0.28%. Regarding short-term risk, SUVEN.NS is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check NEULANDLAB.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, NEULANDLAB.BO has a market cap of 281.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while NEULANDLAB.BO trades at ₹21,891.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas NEULANDLAB.BO's P/E ratio is 55.65. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to NEULANDLAB.BO's ROE of +0.28%. Regarding short-term risk, SUVEN.NS is more volatile compared to NEULANDLAB.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check NEULANDLAB.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, PPLPHARMA.NS has a market cap of 265.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while PPLPHARMA.NS trades at ₹200.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas PPLPHARMA.NS's P/E ratio is -171.22. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, SUVEN.NS is less volatile compared to PPLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check PPLPHARMA.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, PPLPHARMA.BO has a market cap of 264.5B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while PPLPHARMA.BO trades at ₹200.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas PPLPHARMA.BO's P/E ratio is -170.82. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, SUVEN.NS is less volatile compared to PPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check PPLPHARMA.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, SUVEN.NS is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check PEL.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SHILPAMED.NS has a market cap of 210B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SHILPAMED.NS trades at ₹1,073.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SHILPAMED.NS's P/E ratio is 68.21. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SHILPAMED.NS's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check SHILPAMED.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GRANULES.BO has a market cap of 208.2B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GRANULES.BO trades at ₹836.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GRANULES.BO's P/E ratio is 31.98. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, SUVEN.NS is more volatile compared to GRANULES.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check GRANULES.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GRANULES.NS has a market cap of 207.3B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GRANULES.NS trades at ₹836.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GRANULES.NS's P/E ratio is 31.78. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, SUVEN.NS is more volatile compared to GRANULES.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check GRANULES.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, CAPLIPOINT.BO has a market cap of 203.8B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while CAPLIPOINT.BO trades at ₹2,679.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas CAPLIPOINT.BO's P/E ratio is 31.48. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, SUVEN.NS is less volatile compared to CAPLIPOINT.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check CAPLIPOINT.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, CAPLIPOINT.NS has a market cap of 203.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while CAPLIPOINT.NS trades at ₹2,679.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas CAPLIPOINT.NS's P/E ratio is 31.49. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, SUVEN.NS is less volatile compared to CAPLIPOINT.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check CAPLIPOINT.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, COHANCE.NS has a market cap of 174.8B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while COHANCE.NS trades at ₹457.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas COHANCE.NS's P/E ratio is 138.20. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to COHANCE.NS's ROE of +0.03%. Regarding short-term risk, SUVEN.NS is more volatile compared to COHANCE.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check COHANCE.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, COHANCE.BO has a market cap of 174.5B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while COHANCE.BO trades at ₹457.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas COHANCE.BO's P/E ratio is 144.41. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to COHANCE.BO's ROE of +0.03%. Regarding short-term risk, SUVEN.NS is more volatile compared to COHANCE.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check COHANCE.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ALIVUS.NS has a market cap of 169.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ALIVUS.NS trades at ₹1,384.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ALIVUS.NS's P/E ratio is 27.43. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, SUVEN.NS is more volatile compared to ALIVUS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ALIVUS.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ALIVUS.BO has a market cap of 169.8B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ALIVUS.BO trades at ₹1,383.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ALIVUS.BO's P/E ratio is 28.15. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ALIVUS.BO's ROE of +0.10%. Regarding short-term risk, SUVEN.NS is more volatile compared to ALIVUS.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ALIVUS.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ERIS.BO has a market cap of 164.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ERIS.BO trades at ₹1,187.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ERIS.BO's P/E ratio is 38.51. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, SUVEN.NS is more volatile compared to ERIS.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ERIS.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ERIS.NS has a market cap of 164.2B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ERIS.NS trades at ₹1,184.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ERIS.NS's P/E ratio is 33.51. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, SUVEN.NS is more volatile compared to ERIS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ERIS.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, APLLTD.NS has a market cap of 164B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while APLLTD.NS trades at ₹834.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas APLLTD.NS's P/E ratio is 21.84. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, SUVEN.NS is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check APLLTD.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, APLLTD.BO has a market cap of 163.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while APLLTD.BO trades at ₹833.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas APLLTD.BO's P/E ratio is 21.83. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, SUVEN.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check APLLTD.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, JUBLPHARMA.BO has a market cap of 156.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while JUBLPHARMA.BO trades at ₹988.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas JUBLPHARMA.BO's P/E ratio is 41.00. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to JUBLPHARMA.BO's ROE of +0.05%. Regarding short-term risk, SUVEN.NS is less volatile compared to JUBLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check JUBLPHARMA.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, JUBLPHARMA.NS has a market cap of 156.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while JUBLPHARMA.NS trades at ₹989.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas JUBLPHARMA.NS's P/E ratio is 40.99. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to JUBLPHARMA.NS's ROE of +0.05%. Regarding short-term risk, SUVEN.NS is more volatile compared to JUBLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check JUBLPHARMA.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ASTRAZEN.BO has a market cap of 149.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ASTRAZEN.BO trades at ₹5,983.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ASTRAZEN.BO's P/E ratio is 88.19. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ASTRAZEN.BO's ROE of +0.20%. Regarding short-term risk, SUVEN.NS is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ASTRAZEN.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ASTRAZEN.NS has a market cap of 149.5B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ASTRAZEN.NS trades at ₹5,980.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ASTRAZEN.NS's P/E ratio is 88.15. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ASTRAZEN.NS's ROE of +0.20%. Regarding short-term risk, SUVEN.NS is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check ASTRAZEN.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, NATCOPHARM.NS has a market cap of 147.5B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while NATCOPHARM.NS trades at ₹823.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas NATCOPHARM.NS's P/E ratio is 13.58. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to NATCOPHARM.NS's ROE of +0.13%. Regarding short-term risk, SUVEN.NS is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check NATCOPHARM.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, NATCOPHARM.BO has a market cap of 147.5B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while NATCOPHARM.BO trades at ₹823.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas NATCOPHARM.BO's P/E ratio is 13.59. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to NATCOPHARM.BO's ROE of +0.13%. Regarding short-term risk, SUVEN.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check NATCOPHARM.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, SUVEN.NS is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check GLS.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, SUVEN.NS is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check GLS.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SUDEEPPHRM.NS has a market cap of 130.8B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SUDEEPPHRM.NS trades at ₹1,158.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SUDEEPPHRM.NS's P/E ratio is 71.64. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, SUVEN.NS is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check SUDEEPPHRM.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AKUMS.NS has a market cap of 124.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AKUMS.NS trades at ₹814.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AKUMS.NS's P/E ratio is 43.13. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AKUMS.NS's ROE of +0.09%. Regarding short-term risk, SUVEN.NS is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check AKUMS.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to CAPPL.BO's ROE of +0.05%. Regarding short-term risk, SUVEN.NS is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check CAPPL.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SHILPAMED.BO has a market cap of 104.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SHILPAMED.BO trades at ₹1,072.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SHILPAMED.BO's P/E ratio is 70.37. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SHILPAMED.BO's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to SHILPAMED.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check SHILPAMED.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, VIYASH.NS has a market cap of 101.8B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while VIYASH.NS trades at ₹233.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas VIYASH.NS's P/E ratio is 56.06. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, SUVEN.NS is more volatile compared to VIYASH.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check VIYASH.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, STAR.NS has a market cap of 100.3B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while STAR.NS trades at ₹1,088.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas STAR.NS's P/E ratio is 16.37. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to STAR.NS's ROE of +0.22%. Regarding short-term risk, SUVEN.NS is more volatile compared to STAR.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check STAR.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, STAR.BO has a market cap of 99.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while STAR.BO trades at ₹1,087.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas STAR.BO's P/E ratio is 16.36. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to STAR.BO's ROE of +0.22%. Regarding short-term risk, SUVEN.NS is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check STAR.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AARTIPHARM.NS has a market cap of 88.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AARTIPHARM.NS trades at ₹975.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AARTIPHARM.NS's P/E ratio is 41.47. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AARTIPHARM.NS's ROE of +0.10%. Regarding short-term risk, SUVEN.NS is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check AARTIPHARM.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, PGHL.NS has a market cap of 88.1B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while PGHL.NS trades at ₹5,306.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas PGHL.NS's P/E ratio is 24.69. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to PGHL.NS's ROE of +0.62%. Regarding short-term risk, SUVEN.NS is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check PGHL.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, PGHL.BO has a market cap of 88B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while PGHL.BO trades at ₹5,301.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas PGHL.BO's P/E ratio is 24.61. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to PGHL.BO's ROE of +0.62%. Regarding short-term risk, SUVEN.NS is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check PGHL.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AARTIPHARM.BO has a market cap of 87.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AARTIPHARM.BO trades at ₹974.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AARTIPHARM.BO's P/E ratio is 41.46. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AARTIPHARM.BO's ROE of +0.10%. Regarding short-term risk, SUVEN.NS is more volatile compared to AARTIPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check AARTIPHARM.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, MOREPENLAB.NS has a market cap of 78.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while MOREPENLAB.NS trades at ₹143.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas MOREPENLAB.NS's P/E ratio is 56.13. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to MOREPENLAB.NS's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check MOREPENLAB.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, MOREPENLAB.BO has a market cap of 78.8B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while MOREPENLAB.BO trades at ₹143.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas MOREPENLAB.BO's P/E ratio is 83.09. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to MOREPENLAB.BO's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check MOREPENLAB.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, BLISSGVS.NS has a market cap of 71.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while BLISSGVS.NS trades at ₹676.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas BLISSGVS.NS's P/E ratio is 52.54. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check BLISSGVS.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, BLISSGVS.BO has a market cap of 71.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while BLISSGVS.BO trades at ₹670.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas BLISSGVS.BO's P/E ratio is 52.05. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check BLISSGVS.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SUVEN.BO has a market cap of 69.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SUVEN.BO trades at ₹309.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SUVEN.BO's P/E ratio is -24.93. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SUVEN.BO's ROE of -1.12%. Regarding short-term risk, SUVEN.NS is more volatile compared to SUVEN.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check SUVEN.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, INNOVACAP.NS has a market cap of 65.3B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while INNOVACAP.NS trades at ₹1,141.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas INNOVACAP.NS's P/E ratio is 53.68. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to INNOVACAP.NS's ROE of +0.15%. Regarding short-term risk, SUVEN.NS is less volatile compared to INNOVACAP.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check INNOVACAP.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SPARC.NS has a market cap of 63.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SPARC.NS trades at ₹196.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SPARC.NS's P/E ratio is 4.11. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SPARC.NS's ROE of +3.19%. Regarding short-term risk, SUVEN.NS is more volatile compared to SPARC.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check SPARC.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SPARC.BO has a market cap of 63.7B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SPARC.BO trades at ₹196.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SPARC.BO's P/E ratio is 4.11. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SPARC.BO's ROE of +3.19%. Regarding short-term risk, SUVEN.NS is less volatile compared to SPARC.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check SPARC.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, IOLCP.NS has a market cap of 63.1B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while IOLCP.NS trades at ₹214.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas IOLCP.NS's P/E ratio is 35.11. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to IOLCP.NS's ROE of +0.09%. Regarding short-term risk, SUVEN.NS is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check IOLCP.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, IOLCP.BO has a market cap of 63B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while IOLCP.BO trades at ₹214.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas IOLCP.BO's P/E ratio is 35.16. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to IOLCP.BO's ROE of +0.09%. Regarding short-term risk, SUVEN.NS is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check IOLCP.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, FDC.BO has a market cap of 54.4B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while FDC.BO trades at ₹334.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas FDC.BO's P/E ratio is 19.33. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is more volatile compared to FDC.BO. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check FDC.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, FDC.NS has a market cap of 54.3B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while FDC.NS trades at ₹333.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas FDC.NS's P/E ratio is 19.30. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is more volatile compared to FDC.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check FDC.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ORCHPHARMA.NS has a market cap of 51.1B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ORCHPHARMA.NS trades at ₹1,006.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ORCHPHARMA.NS's P/E ratio is 162.35. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SUVEN.NS is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check ORCHPHARMA.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, ORCHPHARMA.BO has a market cap of 51B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while ORCHPHARMA.BO trades at ₹1,006.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas ORCHPHARMA.BO's P/E ratio is 78.40. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, SUVEN.NS is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check ORCHPHARMA.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, NOVARTIND.BO has a market cap of 50.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while NOVARTIND.BO trades at ₹2,049.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas NOVARTIND.BO's P/E ratio is 53.32. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check NOVARTIND.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, NOVARTIND.NS has a market cap of 50.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while NOVARTIND.NS trades at ₹2,051.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas NOVARTIND.NS's P/E ratio is 53.37. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check NOVARTIND.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SEQUENT.NS's ROE of +0.08%. Regarding short-term risk, SUVEN.NS is more volatile compared to SEQUENT.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check SEQUENT.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to SEQUENT.BO's ROE of +0.08%. Regarding short-term risk, SUVEN.NS is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check SEQUENT.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, RPGLIFE.BO has a market cap of 48.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while RPGLIFE.BO trades at ₹2,937.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas RPGLIFE.BO's P/E ratio is 42.18. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, SUVEN.NS is less volatile compared to RPGLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check RPGLIFE.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, RPGLIFE.NS has a market cap of 48.5B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while RPGLIFE.NS trades at ₹2,933.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas RPGLIFE.NS's P/E ratio is 42.12. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, SUVEN.NS is more volatile compared to RPGLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for SUVEN.NS.Check RPGLIFE.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GUFICBIO.NS has a market cap of 42.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GUFICBIO.NS trades at ₹427.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GUFICBIO.NS's P/E ratio is 58.40. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GUFICBIO.NS's ROE of +0.11%. Regarding short-term risk, SUVEN.NS is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check GUFICBIO.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GUFICBIO.BO has a market cap of 42.9B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GUFICBIO.BO trades at ₹427.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GUFICBIO.BO's P/E ratio is 58.38. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GUFICBIO.BO's ROE of +0.11%. Regarding short-term risk, SUVEN.NS is less volatile compared to GUFICBIO.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check GUFICBIO.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GUJTHEM.BO has a market cap of 42.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GUJTHEM.BO trades at ₹390.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GUJTHEM.BO's P/E ratio is 87.37. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GUJTHEM.BO's ROE of +0.18%. Regarding short-term risk, SUVEN.NS is less volatile compared to GUJTHEM.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check GUJTHEM.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, GUJTHEM.NS has a market cap of 42.5B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while GUJTHEM.NS trades at ₹390.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas GUJTHEM.NS's P/E ratio is 90.70. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to GUJTHEM.NS's ROE of +0.18%. Regarding short-term risk, SUVEN.NS is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check GUJTHEM.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AARTIDRUGS.NS has a market cap of 39.1B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AARTIDRUGS.NS trades at ₹428.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AARTIDRUGS.NS's P/E ratio is 20.18. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, SUVEN.NS is less volatile compared to AARTIDRUGS.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check AARTIDRUGS.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, AARTIDRUGS.BO has a market cap of 39.1B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while AARTIDRUGS.BO trades at ₹428.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas AARTIDRUGS.BO's P/E ratio is 20.16. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, SUVEN.NS is less volatile compared to AARTIDRUGS.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check AARTIDRUGS.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, UNICHEMLAB.NS has a market cap of 38.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while UNICHEMLAB.NS trades at ₹548.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas UNICHEMLAB.NS's P/E ratio is 12.66. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check UNICHEMLAB.NS's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, UNICHEMLAB.BO has a market cap of 38.6B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while UNICHEMLAB.BO trades at ₹547.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas UNICHEMLAB.BO's P/E ratio is 12.64. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, SUVEN.NS is less volatile compared to UNICHEMLAB.BO. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check UNICHEMLAB.BO's competition here

Suven Life Sciences Limited (NSE: SUVEN.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SUVEN.NS stands at 70.5B. In comparison, INDSWFTLAB.NS has a market cap of 34.8B. Regarding current trading prices, SUVEN.NS is priced at ₹309.15 on the NSE, while INDSWFTLAB.NS trades at ₹400.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SUVEN.NS currently has a P/E ratio of -21.76, whereas INDSWFTLAB.NS's P/E ratio is 58.71. In terms of profitability, SUVEN.NS's ROE is -1.12%, compared to INDSWFTLAB.NS's ROE of +0.04%. Regarding short-term risk, SUVEN.NS is less volatile compared to INDSWFTLAB.NS. This indicates lower risk in terms of short-term price fluctuations for SUVEN.NS.Check INDSWFTLAB.NS's competition here